Emergence of the erythropoietin/erythropoietin receptor system as a novel cardiovascular therapeutic target.


Although hypoxia and ischemia are known to be involved in the pathogenesis of cardiovascular disease, specific therapeutic targets still remain elusive. To address this important issue, we have performed 2 series of experimental studies, aiming at erythropoietin (Epo)/Epo receptor (EpoR) based on the following backgrounds. Epo has long been regarded as a… (More)
DOI: 10.1097/FJC.0b013e318235e7bb


  • Presentations referencing similar topics